Atlas Trials

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

Clinical trial NCT00802841 · COMPLETED

Trial details

NCT number
NCT00802841
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Myelogenous Leukemia
Start date
2009-05-01
Primary completion
2014-07-01
Enrollment
191

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.